Literature DB >> 23296115

Acute myeloid leukaemia in 2012: En route to improved treatment options.

Heiko Becker1, Clara D Bloomfield.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23296115     DOI： 10.1038/nrclinonc.2012.239

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

Authors:  E L Sievers; R A Larson; E A Stadtmauer; E Estey; B Löwenberg; H Dombret; C Karanes; M Theobald; J M Bennett; M L Sherman; M S Berger; C B Eten; M R Loken; J J van Dongen; I D Bernstein; F R Appelbaum
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

2.  Control of acute myeloid leukemia relapse--dance between KIRs and HLA.

Authors:  Jeffrey S Miller; Bruce R Blazar
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

3.  The origin and evolution of mutations in acute myeloid leukemia.

Authors:  John S Welch; Timothy J Ley; Daniel C Link; Christopher A Miller; David E Larson; Daniel C Koboldt; Lukas D Wartman; Tamara L Lamprecht; Fulu Liu; Jun Xia; Cyriac Kandoth; Robert S Fulton; Michael D McLellan; David J Dooling; John W Wallis; Ken Chen; Christopher C Harris; Heather K Schmidt; Joelle M Kalicki-Veizer; Charles Lu; Qunyuan Zhang; Ling Lin; Michelle D O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Lucinda A Fulton; Vincent J Magrini; Sean D McGrath; Ryan T Demeter; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd N Wylie; Jason R Walker; Mark A Watson; Sharon E Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Jacqueline E Payton; Jack D Baty; Shashikant Kulkarni; Jeffery M Klco; Michael H Tomasson; Peter Westervelt; Matthew J Walter; Timothy A Graubert; John F DiPersio; Li Ding; Elaine R Mardis; Richard K Wilson
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

4.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Authors:  Michael Lübbert; Björn H Rüter; Rainer Claus; Claudia Schmoor; Mathias Schmid; Ulrich Germing; Andrea Kuendgen; Volker Rethwisch; Arnold Ganser; Uwe Platzbecker; Oliver Galm; Wolfram Brugger; Gerhard Heil; Björn Hackanson; Barbara Deschler; Konstanze Döhner; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

6.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

7.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

8.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

9.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Jonathan Kell; Sylvie Freeman; Lars Kjeldsen; Ann E Hunter; John Yin; Charles F Craddock; Inge Hoegh Dufva; Keith Wheatley; Donald Milligan
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
  9 in total
  2 in total

1.  p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells.

Authors:  A Trocoli; P Bensadoun; E Richard; G Labrunie; F Merhi; A M Schläfli; D Brigger; S Souquere; G Pierron; J-M Pasquet; P Soubeyran; J Reiffers; E Ségal-Bendirdjian; M P Tschan; M Djavaheri-Mergny
Journal:  Cell Death Differ       Date:  2014-07-18       Impact factor: 15.828

2.  Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.

Authors:  Xiao-Qing Yuan; Dao-Yu Zhang; Han Yan; Yong-Long Yang; Ke-Wei Zhu; Yan-Hong Chen; Xi Li; Ji-Ye Yin; Xiao-Lin Li; Hui Zeng; Xiao-Ping Chen
Journal:  Oncotarget       Date:  2016-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.